A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS（2023）
Key words
hepatic impairment,iberdomide,pharmacokinetics
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined